News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,999 Results
Type
Article (14217)
Company Profile (282)
Press Release (252500)
Section
Business (79588)
Career Advice (153)
Deals (13233)
Drug Delivery (35)
Drug Development (50532)
Employer Resources (32)
FDA (5727)
Job Trends (5133)
News (144586)
Policy (10042)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (911)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21662)
ALS (61)
Alzheimer's disease (825)
Antibody-drug conjugate (ADC) (87)
Approvals (5743)
Artificial intelligence (108)
Autoimmune disease (10)
Automation (5)
Bankruptcy (104)
Best Places to Work (4565)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (45)
Brain cancer (19)
Breast cancer (146)
Cancer (1307)
Cardiovascular disease (108)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (305)
Cervical cancer (8)
Clinical research (40955)
Collaboration (498)
Compensation (219)
Complete response letters (13)
COVID-19 (1034)
CRISPR (37)
C-suite (146)
Cystic fibrosis (76)
Data (1363)
Denatured (11)
Depression (29)
Diabetes (125)
Diagnostics (1292)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (78)
Drug pricing (29)
Drug shortages (3)
Duchenne muscular dystrophy (82)
Earnings (29697)
Editorial (17)
Employer branding (4)
Employer resources (30)
Events (48205)
Executive appointments (402)
FDA (6350)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (465)
Gene editing (88)
Generative AI (9)
Gene therapy (229)
GLP-1 (356)
Government (1076)
Grass and pollen (2)
Guidances (18)
Healthcare (6593)
Huntington's disease (21)
IgA nephropathy (21)
Immunology and inflammation (80)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (57)
Interviews (17)
IPO (7264)
IRA (12)
Job creations (861)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (201)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (186)
Lymphoma (84)
Machine learning (1)
Management (8)
Manufacturing (115)
MASH (48)
Medical device (2592)
Medtech (2593)
Mergers & acquisitions (6255)
Metabolic disorders (363)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (57)
Neuropsychiatric disorders (23)
Neuroscience (1194)
NextGen: Class of 2025 (2020)
Non-profit (852)
Northern California (1551)
Now hiring (21)
Obesity (185)
Opinion (102)
Ovarian cancer (60)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (105)
Partnered (8)
Patents (111)
Patient recruitment (66)
Peanut (35)
People (25539)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14479)
Phase II (19029)
Phase III (12041)
Pipeline (725)
Podcasts (46)
Policy (37)
Postmarket research (860)
Preclinical (6076)
Press Release (30)
Prostate cancer (54)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (273)
Real estate (1416)
Recruiting (12)
Regulatory (8577)
Reports (15)
Research institute (937)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (3)
RSV (10)
Schizophrenia (56)
Series A (91)
Series B (60)
Service/supplier (1)
Sickle cell disease (38)
Southern California (1377)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1973)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (12121)
Vaccines (204)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (126)
Last 7 days (440)
Last 30 days (1616)
Last 365 days (20087)
2025 (4735)
2024 (20576)
2023 (22437)
2022 (26857)
2021 (27838)
2020 (23387)
2019 (16244)
2018 (11759)
2017 (13767)
2016 (11868)
2015 (14378)
2014 (10412)
2013 (7504)
2012 (7547)
2011 (7642)
2010 (7449)
Location
Africa (149)
Alabama (38)
Alaska (2)
Arizona (52)
Arkansas (5)
Asia (17266)
Australia (2919)
California (3522)
Canada (1048)
China (325)
Colorado (137)
Connecticut (153)
Delaware (88)
Europe (37094)
Florida (412)
Georgia (108)
Idaho (16)
Illinois (211)
India (8)
Indiana (87)
Iowa (1)
Japan (71)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (442)
Massachusetts (2774)
Michigan (69)
Minnesota (136)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (882)
New Mexico (12)
New York (956)
North Carolina (520)
North Dakota (4)
Northern California (1551)
Ohio (107)
Oklahoma (9)
Oregon (21)
Pennsylvania (676)
Puerto Rico (3)
Rhode Island (15)
South America (210)
South Carolina (4)
Southern California (1377)
Tennessee (25)
Texas (403)
Utah (48)
Virginia (67)
Washington D.C. (28)
Washington State (321)
Wisconsin (13)
266,999 Results for "prota therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Prota Therapeutics’ CEO Mimi Tang honoured at BioMelbourne Network’s Women in Leadership Awards 2024
Prota Therapeutics ' CEO Professor Mimi Tang has been honoured in the prestigious 2024 BioMelbourne Network Women in Leadership Awards.
April 29, 2024
·
4 min read
Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments
Prota Therapeutics Pty Ltd today announced financing of US$21 million in equity and debt financing.
January 16, 2024
·
4 min read
Drug Development
Global Roundup: Prota’s Immunotherapy Shows Success Against Peanut Allergy
In a Phase IIb study, data showed that Prota Therapeutics’ oral immunotherapy led to 51% of children reaching clinical remission of their peanut allergy compared to placebo. See inside for this and more!
May 18, 2022
·
8 min read
·
Alex Keown
Drug Development
Prota Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients
Prota Therapeutics, an Australian biotechnology company focused on the development of novel oral immunotherapy treatments, has achieved a significant milestone in the treatment of peanut allergy in children.
February 9, 2022
·
6 min read
Prota Therapeutics Achieves 51 Percent Peanut Allergy Remission Rate, First Company to Validate Significant Quality of Life Improvements Compared with Standard Care
Prota Therapeutics Pty Ltd is the first company to validate significant Health-Related Quality of Life improvements, when compared to placebo, in a Phase 2b clinical trial of oral immunotherapy PRT120, in which 51 percent of treated children aged 1-10 years achieved clinical remission.
May 16, 2022
·
4 min read
Press Releases
Protagonist Therapeutics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025
March 19, 2025
·
6 min read
Press Releases
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025
·
1 min read
Phase III
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a chronic blood cancer taking the drug didn’t need to have their blood removed to bring down dangerously high hemocrit levels.
March 3, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
March 5, 2025
·
14 min read
Press Releases
Protagonist Therapeutics Reports Granting of Inducement Awards
January 7, 2025
·
2 min read
1 of 26,700
Next
